

## Request for Prior Authorization TESTOSTERONE PRODUCTS

FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #								Patient name				DOB								
Patient address																				
Provider NPI									Prescriber name			Phone								
Prescriber address									Fa	X										
Pharmacy name A								Ad	Address				Phone							
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.																				
Pharmacy NPI							_		Pharmacy fax	NDC							_			

Prior authorization is required for testosterone products. Payment will be considered with documentation of a specific testicular or hypothalamic/pituitary disease (primary hypogonadism or hypogonadotropic hypogonadism) that results in classic hypogonadism. Requests for FDA approved indications other than hypogonadism will not be subject to prior authorization criteria with adequate documentation of diagnosis. Payment for non-preferred testosterone products will be authorized only for cases in which there is documentation of previous trials and therapy failures with two preferred agents. Requests for erectile dysfunction, infertility, and age-related hypogonadism will not be considered. Payment will be considered under the following conditions:

- 1) Patient is male and 18 years of age or older (or 12 years of age and older for testosterone cypionate); and
- 2) Patient has two (2) morning pre-treatment testosterone levels below the lower limit of the normal testosterone reference range of the individual laboratory used (attach results); and
- 3) Patient has primary hypogonadism or hypogonadotropic hypogonadism (further defined below)
  - Primary hypogonadism (congenital or acquired) caused by testicular failure due to one of the
  - following: cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome, orchiectomy,
  - Klinefelter's syndrome, chemotherapy, toxic damage from alcohol or heavy metals
  - Hypogonadotropic hypogonadism: idiopathic gonadotropin or luteinizing hormone-releasing
  - (LHRH) deficiency, pituitary-hypothalamic injury from tumors, trauma, or radiation
- 4) Patient does not have:
  - Breast or prostate cancer
  - Palpable prostate nodule or prostate-specific antigen (PSA) > 4ng/mL
  - Hematocrit > 50%
  - Untreated severe obstructive sleep apnea
  - Severe lower urinary tract symptoms
  - Uncontrolled or poorly controlled heart failure

If criteria for coverage are met, initial authorizations will be given for 3 months. Requests for continuation of therapy will require the following:

- An updated testosterone level (attach result); and
- Documentation the patient has not experienced a hematocrit > 54% or an increase in PSA >1.4ng/mL in the past 12 months.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

470-5188 (Rev. 6/25) Page 1 of 2

## Request for Prior Authorization TESTOSTERONE PRODUCTS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Preferred  ☐ Testosterone Cypionate ☐ Testosterone Enanthate ☐ Testosterone Gel 1% Packets	Non-Preferred Androgel Aveed Depo-Testosterone Jatenzo	<ul><li></li></ul>	☐ Testosterone Gel Pump ☐ Testosterone Topical Solution ☐ Tlando ☐ Xyosted 6 ☐ Vogelxo								
Strength Dosage Ins	structions	Qu	antity Days Supply								
Complete for diagnosis of hypo	gonadism:										
	Bilateral torsion (Chemotherapy (Chemotherap	Orchitis □ Vanishing tes Foxic damage from alcohol o	stes syndrome								
<ul> <li>─ Hypogonadotropic Hypogonadism:</li> <li>☐ Idiopathic gonadotropin or luteinizing hormone-releasing (LHRH) deficiency</li> <li>☐ Pituitary-hypothalamic injury from tumors, trauma, or radiation</li> </ul>											
Please indicate setting in w	hich medication is to be	administered:									
	List & attach results of two (2) morning pre-treatment testosterone levels below the lower limit of the normal testosterone reference range of the individual laboratory used:										
Level 1:	Date:	Level 2:	Date:								
Does patient have any of the Breast or prostate cancer: Palpable prostate nodule or period Hematocrit > 50%: Untreated severe obstructive Severe lower urinary tract synuncontrolled or poorly control	rostate-specific antigen (F sleep apnea: nptoms:	☐ Yes PSA) > 4ng/mL: ☐ Yes	<ul> <li>No</li> <li>No</li> <li>No</li> <li>No</li> <li>No</li> <li>No</li> <li>No</li> </ul>								
Renewal Requests:											
List & attach updated testos	List & attach updated testosterone level: Level:										
Has patient experienced the following in the past 12 months:											
Hematocrit > 54%:	Hematocrit > 54%:										
Increase in PSA > 1.4ng/mL:  Yes No Most recent lab date:											
Other medical conditions to consider:											
Attach lab results and other documentation as necessary.											
Prescriber signature (Must match	prescriber listed above.)	Date of submission									

**IMPORTANT NOTE:** In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.

470-5188 (Rev. 6/25) Page 2 of 2